Two companies are developing pain inhibitors for market, with Neil Singla serving as chief medical officer of Latigo, and the FDA granting fast-track designation for a drug candidate.
1 report, 1 independent
Updated Aug 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Two companies are developing pain inhibitors for market, with Neil Singla serving as chief medical officer of Latigo, and the FDA granting fast-track designation for a drug candidate.
Who's involved
What this event is mainly aboutFDANeil Singla